PR: Atossa Genetics Inc (NASDAQ: ATOS) shares soared more than 40 percent Thursday after it signed an agreement with a major distributor for an upcoming launch of its FullCyte device used in breast examinations.
Execution detail:
You need to log into your Tradervue account to leave a comment. If you don't have one,
it takes
just a few seconds to sign up, and it's free!